New legislation in Congress would prohibit limiting what pharmacists can tell patients about the cheapest way to pay for their prescriptions; drug companies, researchers, and health officials are trying to develop an overdose-reversal treatment that is more successful than naloxone against synthetic opioids; a Texas lawsuit seeking to strike down the Affordable Care Act is being opposed by 16 Democratic attorneys general.
New legislation in Congress would prohibit insurers or pharmacy benefit managers from limiting what pharmacists can tell patients about the cheapest way to pay for their prescriptions. According to The Detroit News, some prescriptions may be cheaper for customers if they pay in cash, rather than their insurance co-pay, but pharmacists were unable to tell them that. The legislation is being sponsored by Senators Debbie Stabenow, D-Michigan, and Susan Collins, R-Maine. Research has shown customers overpay for prescriptions 23% of the time.
Naloxone is widely used to reverse opioid overdoses, but it has limited success against synthetic opioids. With the use of synthetic opioids on the rise, drug companies, researchers, and health officials are trying to develop a new treatment that may replace naloxone in certain cases, reported STAT. One option being pursued is tweaking buprenorphine, which is currently used to treat addiction, but may also be able to reverse an overdose with some changes.
A Texas lawsuit seeking to strike down the Affordable Care Act (ACA) has strong opposition from 16 Democratic attorneys general (AGs), led by California AG Xavier Becerra. As a result, there is a showdown between red and blue states with 19 Republican-led states joining Texas’ case, according to The New York Times. Texas’ lawsuit claims the repeal of the individual mandate as part of the Republican tax bill means that the ACA is no longer valid.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More